<DOC>
	<DOCNO>NCT03099655</DOCNO>
	<brief_summary>The purpose clinical study evaluate safety efficacy Attain Stability Quadripolar Left Ventricular ( LV ) lead ( Model 4798 ) .</brief_summary>
	<brief_title>Attain Stability™ Quad Clinical Study</brief_title>
	<detailed_description>The Attain Stability Quad Clinical Study prospective , non-randomized , multi-site , global , investigational Device Exemption ( IDE ) , interventional clinical study . The purpose clinical study evaluate safety efficacy Attain Stability™ Quad MRI SureScan LV Lead ( Model 4798 ) patient indicate de novo LV lead implant . This assess primary safety primary efficacy endpoint . All subject include study implant Medtronic market release de novo CRT-P CRT-D device Attain Stability Quad MRI SureScan LV Lead ( Model 4798 ) . Up 471 subject enrol study 471 Stability Quad MRI SureScan LV Lead ( Model 4798 ) implant , ensure minimum effective sample size 400 Model 4798 lead implant 6 month post implant follow visit ( assume 15 % attrition ) . The study expect conducted 56 site worldwide .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Patient meet CRT implant criterion determine local regulatory and/or hospital policy Patient ( legally authorize representative ) sign date studyspecific Informed Consent Form Patient 18 year age old , legal age give inform consent per local national law Patient expect remain available followup visit Patient previous unsuccessful LV lead implant attempt Patient previous CRT system LV lead implant ( example , transvenous epicardial ) Patient currently implant recall ( i.e . marketwithdrawn , recall safety alert ) RA and/or RV lead Patient know coronary venous vasculature inadequate lead placement Patient unstable angina pectoris acute myocardial infarction ( MI ) within past 30 day Patient coronary artery bypass graft ( CABG ) percutaneous transluminal coronary angioplasty ( PTCA ) within past 90 day Patient contraindication standard transvenous cardiac pacing ( e.g. , mechanical right heart valve ) Patient heart transplant ( patient wait heart transplant allow study ) Patient know renal insufficiency would prevent receive occlusive venogram implant procedure Patient contraindicate &lt; 1mg dexamethasone acetate Patient enrol concurrent drug and/or device study may confound result study Patient terminal illness expect survive six month Patient meet exclusion criterion require local law ( e.g . age , pregnancy , breast feeding , etc . ) Patient unable tolerate urgent thoracotomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Cardiac Pacing</keyword>
	<keyword>Cardiac Resynchronization Therapy</keyword>
	<keyword>Left Ventricular Lead</keyword>
</DOC>